Key features and details
- Rabbit polyclonal to HSV1 (Biotin)
- Suitable for: ELISA, ICC/IF
- Conjugation: Biotin
- Isotype: IgG
Product nameAnti-HSV1 antibody (Biotin)
See all HSV1 primary antibodies
DescriptionRabbit polyclonal to HSV1 (Biotin)
Tested applicationsSuitable for: ELISA, ICC/IFmore details
Strain F (Human).
Purified IgG fraction covalently coupled with the N-Hydroxysuccinimide ester of Biotin under mild conditions to give a high degree of substitution.
Storage instructionsShipped at 4°C. Store at +4°C short term (1-2 weeks). Store at -20°C or -80°C. Avoid freeze / thaw cycle.
Storage bufferpH: 7.20
Preservative: 0.1% Sodium azide
Constituent: 0.0268% PBS
Concentration information loading...
PurityProtein A purified
Our Abpromise guarantee covers the use of ab19946 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|ELISA||Use at an assay dependent dilution.|
|ICC/IF||Use at an assay dependent dilution.|
RelevanceHerpes simplex type 1 (HSV-1) belongs to a family that includes HSV-2, Epstein-Barr virus (EBV) and Varicella zoster (chicken pox) virus amongst others. HSV-1 and HSV-2 are extremely difficult to distinguish from each other. Members of this family have a characteristic virion structure. The double stranded DNA genome is contained within an icosahedral capsid embedded in a proteinaceous layer (tegument) and surrounded by a lipid envelope, derived from the nuclear membrane of the last host, which is decorated with virus-specific glycoproteins spikes. These viruses are capable of entering a latent phase where the host shows no visible sign of infection and levels of infectious agent become very low.
- Herpes simplex virus 1 antibody
- Herpes simplex virus antibody
- Herpes simplex virus type 1 antibody
To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.
ab19946 has been referenced in 1 publication.
- Ylösmäki E et al. Personalized Cancer Vaccine Platform for Clinically Relevant Oncolytic Enveloped Viruses. Mol Ther 26:2315-2325 (2018). PubMed: 30005865